Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.

Lung cancer (Amsterdam, Netherlands) - 1 Nov 2020

Gao Ge, Liao Weiting, Ma Qizhi, Zhang Benxia, Chen Yue, Wang Yongsheng

Abstract excerpt

OBJECTIVES: The efficacy of anti- programmed cell death 1 (PD-1)/PD-1 ligand (PD-L1) immune checkpoint inhibitors remains controversial in patients with KRAS mutation. In addition, whether and how KRAS gene and its mutant subtypes might influence immunity has not been clarified yet. Here we examine some important biomarkers for the efficacy of immunotherapy in specific KRAS subtypes. MATERIALS AND METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Proteomics

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 32956987
DOI: 10.1016/j.lungcan.2020.09.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.PMID 32956987Read ↗

Unveiling the role of KRAS in tumor immune microenvironment.Semantic proximity Read ↗

KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

Clinicopathological Characteristics and Prognostic Impact of KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

[Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].Semantic proximity Read ↗

Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.Semantic proximity Read ↗

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.Semantic proximity Read ↗

Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS G12V Mutations.Semantic proximity Read ↗

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomasSemantic proximity Read ↗

Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma.Semantic proximity Read ↗

Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.Semantic proximity Read ↗

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.Semantic proximity Read ↗

Exploration of Tumor Mutation Burden Combined with Immune Infiltrates in the Prognosis of Lung AdenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.